Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems

Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems

As more knowledge on molecular alterations favoring carcinogenesis and spreading of gastroenteropancreatic endocrine tumors has become available, a number of targeted agents interfering with key growth and angiogenic pathways have been explored in preclinical and clinical studies. The mTOR inhibitor...

Full description

Bibliographic Details
Main Authors:	Gianfranco Delle Fave, Detlef K. Bartsch, Francesco Panzuto, Maria Rinzivillo, Volker Fendrich, Gabriele Capurso
Format:	Article
Language:	English
Published:	MDPI AG 2012-12-01
Series:	International Journal of Molecular Sciences
Subjects:	gastroenteropancreatic endocrine tumors target therapy mTOR angiogenesis Src hedgehog combined treatment resistance
Online Access:	http://www.mdpi.com/1422-0067/14/1/30

Similar Items

Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors
by: Paragliola RM, et al.
Published: (2016-10-01)

Research Progress of Gastroenteropancreatic Neuroendocrine Neoplasm
by: LUO Wenhao, et al.
Published: (2018-01-01)

Liver metastases in gastroenteropancreatic neuroendocrine tumours – treatment methods
by: Paweł Gut
Published: (2020-01-01)

Development and Maturation of Endocrine Cells of the Gastrointestinal System
by: Sinagoga, Katie Lynn
Published: (2017)

A NEW INCOME IN PEDIATRIC PATHOLOGY: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS. PART I: PANCREATIC TUMORS
by: Smaranda DIACONESCU, et al.
Published: (2013-03-01)

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
by: Bongiovanni A, et al.
Published: (2015-12-01)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
by: Luise Spormann, et al.
Published: (2020-07-01)

Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China
by: Cheng Fang, et al.
Published: (2017-06-01)

Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors
by: Andrea Sansone, et al.
Published: (2019-08-01)

Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience
by: Tuğba Akın Telli, et al.
Published: (2020-09-01)

Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm
by: Yuhong Wang, et al.
Published: (2018-06-01)

Role of endoscopic submucosal dissection in treatment of rectal gastroenteropancreatic neuroendocrine neoplasms
by: Michał Spychalski, et al.
Published: (2016-12-01)

Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases
by: Bruna Estrozi, et al.
Published: (2011-01-01)

Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
by: Justyna Kikut, et al.
Published: (2020-06-01)

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
by: Giovanni Centonze, et al.
Published: (2021-04-01)

Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
by: Ana P. Santos, et al.
Published: (2018-08-01)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
by: Beata Kos-Kudła, et al.
Published: (2017-06-01)

Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995–2012) in South China
by: Wang Yu-hong, et al.
Published: (2012-11-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
by: Ström T, et al.
Published: (2019-10-01)

Extracellular Vesicle Activation of Latent HIV-1 Is Driven by EV-Associated c-Src and Cellular SRC-1 via the PI3K/AKT/mTOR Pathway
by: Robert A. Barclay, et al.
Published: (2020-06-01)

Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
by: Luigi Barrea, et al.
Published: (2021-07-01)

Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients
by: Kiwoon Baeg, et al.
Published: (2021-02-01)

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness
by: Luigi Barrea, et al.
Published: (2018-12-01)

Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study
by: Huiying Shi, et al.
Published: (2018-07-01)

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
by: J. Smith-Palmer, et al.
Published: (2021-01-01)

LAT-1 and GLUT-1 Carrier Expression and Its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors
by: Miguel Sampedro-Núñez, et al.
Published: (2020-10-01)

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
by: Muhammad Wasif Saif, et al.
Published: (2018-10-01)

Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa
by: Daleen Geldenhuys, et al.
Published: (2020-10-01)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
by: Thomas Gress, et al.
Published: (2012-02-01)

mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
by: Sara Zanini, et al.
Published: (2020-11-01)

Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population‐based study
by: Qing Zhong, et al.
Published: (2018-07-01)

Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection
by: Yang Lv, et al.
Published: (2019-04-01)

The role of the spleen tyrosine kinase in activating the MTORC1 pathway in pancreatic cancer cell lines
by: Villait, Akash
Published: (2020)

Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9
by: Min Jiang, et al.
Published: (2013-01-01)

The immunomodulatory effects of endocrine therapy in breast cancer
by: Huanhuan Huang, et al.
Published: (2021-01-01)

Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm
by: Huiying Shi, et al.
Published: (2020-09-01)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
by: Baptiste Camus, et al.
Published: (2021-03-01)

Tumeurs neuroendocrines gastroentéropancréatiques : recherche de nouveaux mécanismes de progression tumorale et de nouvelles cibles thérapeutiques
by: Bollard, Julien
Published: (2014)

TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis
by: Guo-sheng Zhao, et al.
Published: (2018-08-01)

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
by: Daniele Presti, et al.
Published: (2019-08-01)